SUBSTANCE FOR TREATING AND/OR PREVENTING TUMORS, AND DESIGN METHOD AND PREPARATION METHOD THEREOF

Abstract

Provided is a method of designing and preparing a substance for treating and/or preventing a tumor, wherein, a stable structure corresponding to a tumor-related substance is used as the substance for treating and/or preventing the tumor. The essence of disease is the imbalance of organism structural system. The imbalance of the structure of substance in the organism structure system will cause diseases related to the substance. Disclosed is a method that the organism regulates genes or the expression of genes, restores the balance of the structures of substances in the organism structural system, and treats and/or prevents a disease related to the tumor, through the self-adaptation and self-organization of the structure system of the organism after recognizing the stable structure corresponding to the substance.

Claims

1. A method of designing a substance for treating and/or preventing a tumor, wherein, a stable structure corresponding to a tumor-related substance is used as the substance for treating and/or preventing the tumor; the stable structure corresponding to the substance is a structure of the substance in solid form under high temperature over 500° C.

2. The method according to claim 1, wherein, the stable structure corresponding to the tumor-related substance is selected from one or more stable structure of the group consisting of: (1) a stable structure corresponding to a substance that causes a tumor lesion in an organism or the corresponding substance thereof that does not cause a tumor lesion; (2) a stable structure corresponding to the cells, tissues or organs where the tumor occurs; (3) a stable structure corresponding to the healthy cell, tissue or organ corresponding to the primary site of the tumor; (4) a stable structure corresponding to a substance containing the substance in any of the above (1) to (3).

3-41. (canceled)

42. The method according to claim 1, wherein, the tumor is selected from the group consisting of: an epithelial tissue tumor, a skin tumor, a gastric tumor, an esophageal tumor, a colorectal tumor, a liver tumor, a lung tumor, a nasopharyngeal tumor, a breast tumor, a bladder tumor, a renal pelvic tumor, a cervical tumor, a uterine tumor, a prostate tumor, an ovarian tumor, a lymphoma, a thyroid tumor, a mesenchymal tissue tumor, rhabdomyosarcoma, lipoma, osteosarcoma, hemangioma, lymphangioma, leiomyoma of intestinal wall, periosteal chondroma, an intracranial tumor, schwannoma, neurofibroma, retinoblastoma, malignant melanoma, spermatocytoma, granulosa cell tumor, Ewing's sarcoma, neuroectodermal tumor, leukemia.

43. The method according to claim 1, wherein, the tumor is selected from the group consisting of: a lung tumor, a gastric tumor, a liver tumor.

44. The method according to claim 1, wherein, the stable structure corresponding to the tumor-related substance is the stable structure corresponding to the healthy cells, tissues or organs of a swine corresponding to the primary site of the tumor.

45. A method of preparing the substance for treating and/or preventing a tumor, wherein, the method comprises high-temperature carbonization for a substance selected from the group consisting of: (1) a substance that causes a tumor lesion in an organism or the corresponding substance thereof that does not cause a tumor lesion; (2) the cells, tissues or organs where the tumor occurs; (3) the healthy cell, tissue or organ corresponding to the primary site of the tumor; (4) a substance containing the substance in any of the above (1) to (3).

46. The method according to claim 45, wherein, the high-temperature carbonization is performed under high temperature over 500° C.

47. The method according to claim 45, wherein, the tumor is selected from the group consisting of: an epithelial tissue tumor, a skin tumor, a gastric tumor, an esophageal tumor, a colorectal tumor, a liver tumor, a lung tumor, a nasopharyngeal tumor, a breast tumor, a bladder tumor, a renal pelvic tumor, a cervical tumor, a uterine tumor, a prostate tumor, an ovarian tumor, a lymphoma, a thyroid tumor, a mesenchymal tissue tumor, rhabdomyosarcoma, lipoma, osteosarcoma, hemangioma, lymphangioma, leiomyoma of intestinal wall, periosteal chondroma, an intracranial tumor, schwannoma, neurofibroma, retinoblastoma, malignant melanoma, spermatocytoma, granulosa cell tumor, Ewing's sarcoma, neuroectodermal tumor, leukemia.

48. The method according to claim 47, wherein, the tumor is selected from the group consisting of: a lung tumor, a gastric tumor, a liver tumor.

49. The method according to claim 45, wherein, the tumor-related substance is the healthy cells, tissues or organs of a swine corresponding to the primary site of the tumor.

50. A substance for treating and/or preventing a tumor, wherein, the substance is a substance in solid form after high-temperature carbonization of the substance selected from the group consisting of: (1) a substance that causes a tumor lesion in an organism or the corresponding substance thereof that does not cause a tumor lesion; (2) the cells, tissues or organs where the tumor occurs; (3) the healthy cell, tissue or organ corresponding to the primary site of the tumor; (4) a substance containing the substance in any of the above (1) to (3).

51. The substance according to claim 50, wherein, the high-temperature carbonization is performed under high temperature over 500° C.

52. The substance according to claim 50, wherein, the tumor is selected from the group consisting of: an epithelial tissue tumor, a skin tumor, a gastric tumor, an esophageal tumor, a colorectal tumor, a liver tumor, a lung tumor, a nasopharyngeal tumor, a breast tumor, a bladder tumor, a renal pelvic tumor, a cervical tumor, a uterine tumor, a prostate tumor, an ovarian tumor, a lymphoma, a thyroid tumor, a mesenchymal tissue tumor, rhabdomyosarcoma, lipoma, osteosarcoma, hemangioma, lymphangioma, leiomyoma of intestinal wall, periosteal chondroma, an intracranial tumor, schwannoma, neurofibroma, retinoblastoma, malignant melanoma, spermatocytoma, granulosa cell tumor, Ewing's sarcoma, neuroectodermal tumor, leukemia.

53. The substance according to claim 50, wherein, the tumor is selected from the group consisting of: a lung tumor, a gastric tumor, a liver tumor.

54. The substance according to claim 50, wherein, the substance is a substance in solid form after high-temperature carbonization of the healthy cells, tissues or organs of a swine corresponding to the primary site of the tumor.

55. A medicament, health product, food, or food additive, comprising the substance according to claim 50.

56. The medicament, health product, food, or food additive according to claim 55, wherein, the substance is a substance in solid form after high-temperature carbonization of the healthy cells, tissues or organs of a swine corresponding to the primary site of the tumor.

57. A method of treating and/or preventing a tumor, comprising administering to a subject in need thereof a therapeutically effective amount of the substance according to claim 50.

58. The method according to claim 57, wherein, the tumor is selected from the group consisting of: an epithelial tissue tumor, a skin tumor, a gastric tumor, an esophageal tumor, a colorectal tumor, a liver tumor, a lung tumor, a nasopharyngeal tumor, a breast tumor, a bladder tumor, a renal pelvic tumor, a cervical tumor, a uterine tumor, a prostate tumor, an ovarian tumor, a lymphoma, a thyroid tumor, a mesenchymal tissue tumor, rhabdomyosarcoma, lipoma, osteosarcoma, hemangioma, lymphangioma, leiomyoma of intestinal wall, periosteal chondroma, neuroectodermal tumor, an intracranial tumor, schwannoma, neurofibroma, retinoblastoma, malignant melanoma, leukemia, spermatocytoma, granulosa cell tumor, Ewing's sarcoma.

59. The method according to claim 58, wherein, the substance is a substance in solid form after high-temperature carbonization of the healthy cells, tissues or organs of a swine corresponding to the primary site of the tumor.

Description

DETAILED DESCRIPTION

[0453] The present disclosure relates to a substance for treating and/or preventing tumors, and design method and preparation method thereof. Those skilled in the art can learn from the content of this article, can use different materials, can improve the process or use other similar process, which are all considered to be included in the present disclosure. In particular, it should be noted that all similar substitutions and modifications are obvious to those skilled in the art, which are all deemed to be included in the present disclosure. The method and product of the present disclosure have been described in the preferred embodiments. It is obvious that the skilled in the art can make appropriate changes and combinations to the methods described herein without departing from the spirit and scope of the present disclosure to implement the present disclosure.

[0454] In order to further understand the present disclosure, the technical solutions in the embodiments of the present disclosure will be clearly and completely described below in conjunction with the Examples. It is understand that the described Examples are only a part of the embodiments of the present disclosure, rather than all the embodiments. Based on the Examples of the present disclosure, all other embodiments obtained by those of ordinary skill in the art without creative work shall fall within the scope of the present disclosure.

[0455] The specific Examples are as follows:

[0456] Example 1: substance for treating and/or preventing lung tumors and method of preparing the substance

[0457] Tumors are gene mutations or abnormal gene expression, which are essentially imbalances of the structural system established by abstract and concrete structures. For example, when the nucleus of a cancer cell is transplanted into a normal fertilized egg, because the genes are in a normal and balanced structural environment, the expression of the genes can return to normal, and the egg can develop into a healthy organism. Therefore, by treating with a normal external structure, the expression of cancer genes can be restored to normal, so that tumor cells can develop into normal cells. Every structure in normal lung cells has a structure that interacts with it, and this interaction achieves a dynamic balance. Such dynamic balance can be disrupted by lung cancer cells. A stable structure corresponding to normal lung cells can be used as the external structure to apply on the organism structural system. Due to the self-adaptive, self-organizing, and self-stabilizing functions of the organism structural system, the organism structural system regulates the expression of genes in structures that interacts with the external structure to standard levels according to the structural information of each structure in the external structure. That is, the structural environment of normal lung cells is used to affect the gene expression of lung cancer cells to restore the dynamic balance of the structures. In this Example, healthy swine lungs are carbonized at high temperature to obtain substances for treating and preventing lung tumors.

[0458] Example 2: Clinical application of the substance prepared in Example 1 on the treatment of lung cancer

[0459] This Example uses the substance prepared in Example 1 above for efficacy verification. Details are as follows:

[0460] 1. Clinical data: A total of 24 patients with lung cancer were recruited, including 12 males and 12 females, aged 45-79 years old. The patients themselves before the treatment were used as controls.

[0461] 2. Diagnosis criteria: Referring to the diagnosis and staging criteria of lung cancer in “Modern Oncology”.

[0462] 3. Treatment: Orally administering to the patient the substance prepared in Example 1 once per day and 3 g each time for continuous 10 days.

[0463] 4. Efficacy evaluation criteria: Complete remission, all the lesions in the body disappear completely for ≥4 weeks; partial remission, the sum of the longest diameters of the lesions reduces by ≥30% for ≥4 weeks; stable disease, the original lesions do not changed significantly and no new lesion appears; progressive disease, the sum of the longest diameters of the lesions increases by ≥20%, and the absolute value increases by >5 mm, or new lesions appear. Total effective rate=(complete remission+partial remission)/total case number×100%.

[0464] 5. Result: After treatment, 18 patients showed complete remission, 2 patients showed partial remission, and 4 patients showed stable disease. The total effective rate was 83.33%.

[0465] Example 3: substance for treating and/or preventing liver tumors and method of preparing the substance

[0466] In this Example, healthy swine livers are carbonized at high temperature to obtain substances for treating and preventing liver tumors.

[0467] Example 4: Clinical application of the substance prepared in Example 3 on the treatment of liver cancer

[0468] This Example uses the substance prepared in Example 3 above for efficacy verification. Details are as follows:

[0469] 1. Clinical data: A total of 10 patients aged 31-80 years old with liver cancer were recruited. The patients themselves before the treatment were used as controls.

[0470] 2. Diagnosis criteria: (1) Excluding patients who have active liver disease, pregnancy, germline embryogenic tumors, metastatic liver cancer, hard liver, liver with a mass, or patients who have characteristic space-occupying lesions in liver as shown by imaging examination; (2) patients who have characteristic space-occupying lesions in liver as shown by two imaging examinations, or patients who have two positive liver cancer markers and characteristic space-occupying lesions in liver as shown by one imaging examination.

[0471] 3. Treatment: Orally administering to the patient the substance prepared in Example 3 once per day and 3 g each time for continuous 10 days.

[0472] 4. Efficacy evaluation criteria: complete remission, baseline lesions disappear for 4 weeks; partial remission, the sum of the long diameters of baseline lesions reduces by ≥30% for 4 weeks; stable disease, the sum of the long diameters of baseline lesions reduces but does not reach the level of partial remission, or increases but does not reach the level of progressive disease; progressive disease, the sum of the long diameters of baseline lesions increases by ≥20%, or new lesions appear. Total effective rate=(complete remission+partial remission)/total case number x 100%.

[0473] 5. Result: 6 patients showed complete remission, 3 patients showed partial remission, and 1 patients showed stable disease. The total effective rate was 90.00%.

[0474] Example 5: substance for treating and/or preventing gastric tumors and method of preparing the substance

[0475] In this Example, healthy swine stomachs are carbonized at high temperature to obtain substances for treating and preventing gastric tumors.

[0476] Example 6: Clinical application of the substance prepared in Example 5 on the treatment of lung cancer

[0477] This Example uses the substance prepared in Example 5 above for efficacy verification. Details are as follows:

[0478] 1. Clinical data: A total of 11 patients aged 28-70 years old with gastric cancer were recruited. The patients themselves before the treatment were used as controls.

[0479] 2. Diagnostic criteria: Referring to the diagnostic criteria for gastric cancer in the “Health Industry Standards of the People's Republic of China: Diagnostic Criteria for Gastric Cancer (WS 316-2010)”.

[0480] 3. Treatment: Orally administering to the patient the substance prepared in Example 5 once per day and 3 g each time for continuous 10 days, for one week.

[0481] 4. Efficacy evaluation criteria: complete remission, lesions disappear for at least 4 weeks; partial remission, the sum of the longest diameters of target lesions reduces by ≥50% for 4 weeks, no new lesion appears; stable disease, the lesions do not significantly change compared with those before the treatment, and no new lesion appears; progressive disease, the sum of the longest diameters of target lesions increases by ≥25%, or the new lesions are malignant. Total effective rate=(complete remission+partial remission)/total case number×100%.

[0482] 5. Result: after the treatment, 6 patients showed complete remission, 3 patients showed partial remission, and 2 patients showed stable disease. The total effective rate was 81.82%.